A Multi-institutional Review of Single-access Percutaneous Nephrolithotomy for Complex Staghorn Stones.


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 14 10 2020
revised: 30 10 2020
accepted: 30 11 2020
pubmed: 2 1 2021
medline: 14 4 2022
entrez: 1 1 2021
Statut: ppublish

Résumé

With the heterogeneous distribution of novel surgical technologies and variable physician training, there is a need to re-evaluate contemporary outcomes of percutaneous nephrolithotomy (PCNL) for complex staghorn stones. To evaluate contemporary outcomes of guideline-supported treatment for patients with staghorn kidney stones using single-access PCNL in multiple North American centers. We performed a multi-institutional retrospective review of staghorn stones managed from January 1, 2017 to January 1, 2019, inclusive. We excluded patients with more than a single percutaneous access per renal unit and those who underwent a concomitant contralateral procedure. Safety (Clavien-Dindo complications) and efficacy in terms of a strictly defined stone-free rate were examined for single-access PCNL performed on staghorn stones with a Guy's stone score of 3-4. We evaluated 301 patients meeting the inclusion criteria with an average age of 57 yr (range 18-87). All stones had a Guy's stone score of 3 (36.2%) or 4 (63.8%). The mean (± standard deviation) stone burden was 191.4 ± 49.8 mm Single-access PCNL for complex staghorn stones is safe and effective. High stone-free rates with minimal morbidity are achievable with current techniques. This study confirms that single-access percutaneous nephrolithotomy provides excellent outcomes in the treatment of complex kidney stones. This surgical technique has both safe and effective outcomes that are reproducible across multiple centers in North America.

Sections du résumé

BACKGROUND BACKGROUND
With the heterogeneous distribution of novel surgical technologies and variable physician training, there is a need to re-evaluate contemporary outcomes of percutaneous nephrolithotomy (PCNL) for complex staghorn stones.
OBJECTIVE OBJECTIVE
To evaluate contemporary outcomes of guideline-supported treatment for patients with staghorn kidney stones using single-access PCNL in multiple North American centers.
DESIGN, SETTING AND PARTICIPANTS METHODS
We performed a multi-institutional retrospective review of staghorn stones managed from January 1, 2017 to January 1, 2019, inclusive. We excluded patients with more than a single percutaneous access per renal unit and those who underwent a concomitant contralateral procedure.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
Safety (Clavien-Dindo complications) and efficacy in terms of a strictly defined stone-free rate were examined for single-access PCNL performed on staghorn stones with a Guy's stone score of 3-4.
RESULTS AND LIMITATIONS CONCLUSIONS
We evaluated 301 patients meeting the inclusion criteria with an average age of 57 yr (range 18-87). All stones had a Guy's stone score of 3 (36.2%) or 4 (63.8%). The mean (± standard deviation) stone burden was 191.4 ± 49.8 mm
CONCLUSIONS CONCLUSIONS
Single-access PCNL for complex staghorn stones is safe and effective. High stone-free rates with minimal morbidity are achievable with current techniques.
PATIENT SUMMARY RESULTS
This study confirms that single-access percutaneous nephrolithotomy provides excellent outcomes in the treatment of complex kidney stones. This surgical technique has both safe and effective outcomes that are reproducible across multiple centers in North America.

Identifiants

pubmed: 33384272
pii: S2405-4569(20)30302-3
doi: 10.1016/j.euf.2020.11.005
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1170-1175

Informations de copyright

Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Tim Large (T)

Department of Urology, Indiana University, Indianapolis, IN, USA.

Mark A Assmus (MA)

Department of Urology, Indiana University, Indianapolis, IN, USA.

Crystal Valadon (C)

Department of Urology, Indiana University, Indianapolis, IN, USA.

Anthony Emmott (A)

Department of Urology, University of British Columbia, Vancouver, Canada.

Connor M Forbes (CM)

Department of Urology, University of British Columbia, Vancouver, Canada.

Deepak Agarwal (D)

Department of Urology, Mayo Clinic, Rochester, MN, USA.

Charles Nottingham (C)

Department of Urology, Indiana University, Indianapolis, IN, USA.

Kymora Scotland (K)

Department of Urology, University of British Columbia, Vancouver, Canada.

Marcelino Rivera (M)

Department of Urology, Mayo Clinic, Rochester, MN, USA.

Ben Chew (B)

Department of Urology, University of British Columbia, Vancouver, Canada.

Amy Krambeck (A)

Department of Urology, Indiana University, Indianapolis, IN, USA. Electronic address: akrambeck@iuhealth.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH